Industry Payments to Physicians for Opioid Products, 2013-2015
Industry Payments to Physicians for Opioid Products, 2013-2015
复制标题
DOI：
10.2105/ajph.2017.303982
复制
发表时间：
2017-09-01
影响因子：
12.7
通讯作者：
Marshall, Brandon D. L.
中科院分区：
文献类型：
--
作者：
Hadland, Scott E.;Krieger, Maxwell S.;Marshall, Brandon D. L.
目标.确定涉及阿片类药物产品从制药行业支付给医生。我们使用了医疗保险和医疗补助服务中心的开放支付计划数据库，以确定2013年8月至2015年12月期间向医生支付的阿片类药物。我们使用中位数、四分位数范围和严重偏态分布的范围来检查根据阿片类药物产品、滥用威慑制剂、支付性质、州和医生专业的支付情况。在研究期间，向68177名医生支付了375266笔非研究阿片类药物相关的款项，总额为46158388美元。收入最高的1%的医生获得了82.5%的美元报酬。滥用威慑制剂占总付款的20.3%，用于成瘾治疗的丁丙诺啡占9.9%。大多数付款是演讲费或酬金（占所有美元的63.2%），而食品和饮料付款最频繁（占所有付款的93.9%）。麻醉科专科医生的年收入最多（中位数= 50美元;四分位数间距= 16 - 151美元）。在为期29个月的研究中，大约每12名美国医生中就有1名接受了涉及阿片类药物的付款。这些发现应该促使研究行业对阿片类药物处方的影响。
Objectives. To identify payments that involved opioid products from the pharmaceutical industry to physicians.Methods. We used the Open Payments program database from the Centers for Medicare and Medicaid Services to identify payments involving an opioid to physicians between August 2013 and December 2015. We used medians, interquartile ranges, and ranges as a result of heavily skewed distributions to examine payments according to opioid product, abuse-deterrent formulation, nature of payment, state, and physician specialty.Results. During the study, 375 266 nonresearch opioid-related payments were made to 68 177 physicians, totaling $46 158 388. The top 1% of physicians received 82.5% of total payments in dollars. Abuse-deterrent formulations constituted 20.3% of total payments, and buprenorphine marketed for addiction treatment constituted 9.9%. Most payments were for speaking fees or honoraria (63.2% of all dollars), whereas food and beverage payments were the most frequent (93.9% of all payments). Physicians specializing in anesthesiology received the most in total annual payments (median = $50; interquartile range = $16-$ 151).Conclusions. Approximately 1 in 12 US physicians received a payment involving an opioid during the 29-month study. These findings should prompt an examination of industry influences on opioid prescribing.